Ex Vivo Normothermic Perfusion in Kidney Transplantation. (KidneyARK)

Ebers Medical Technology

Status: Enrolling

Conditions: Kidney Transplantation

Treatments: Device: Cold preservation; Device: Ex vivo normothermic perfusion

Study type: Interventional

Funder types: Industry

Identifiers

NCT05175885

KidneyARK

Details and patient eligibility

About

A multicenter, prospective and open-label clinical investigation to evaluate the viability, performance and safety of ex vivo normothermic perfusion in kidney transplantation from DCD and DBD donors.

Full description

The Ark Kidney is a medical device for ex vivo normothermic perfusion intended to create the conditions that allow kidneys to be resuscitated and / or preserved prior to transplantation. It consists of a permanent unit, which is retained after each perfusion, and a disposable circuit called the ARK Kidney Kidney Disposable Set (KDS), which must be replaced after perfusion to ensure sterile conditions.

It is a portable organ perfusion system designed to preserve a kidney by continuous perfusion of the donated organ with warm oxygenated perfusate supplemented with erythrocytes from the blood bank. The perfusion solution circulates continuously through the vascular network of the organ in a closed circuit. During perfusion, the system can monitor organ perfusion parameters, as well as the conditions of the perfusion solutions and the volume of urine generated during the perfusion.

The primary objective of the clinical study is to assess the viability, performance and safety of ex vivo normothermic perfusion with the Ark Kidney in kidney transplantation from DCD and DBD donors.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients aged 18 years and older
2. Patients undergoing renal replacement therapy by means of dialysis and included in the waiting list for renal transplantation in their respective site.
3. Candidates to receive a first or second renal transplant from (i) a Maastricht type III (Maastricht classification) controlled DCD donor or (ii) a DBD donor aged 70 years or older.
4. Patients that have given informed consent in written form before their inclusion in the study. In case of compromised mental capacity, the approval and signature of a legal guardian will be required.
5. Patients compliant with the requirements of the study and without impediments to follow the instructions throughout the 1-year duration of the study.
6. Patients that meet the acceptance criteria for kidney transplant recipients established in the clinical site in agreement with usual clinical practice.

Exclusion criteria

1. Two or more previous kidney transplantations

2. Dual kidney transplantation or multivisceral transplantation (e.g. a pancreas-kidney transplantation)

3. Recipients of an organ with any of the following characteristics:

   1. Expected cold ischemia time before EVNP > 20 hours
   2. Organ from hepatitis B surface antigen-positive or hepatitis C viremic donor
   3. Organ with multiple arteries

4. Recipients with body mass index (BMI) > 40 kg/m2

5. Diagnosis of focal segmental glomerulosclerosis (FSGS) or membranoproliferative glomerulonephritis with high recurrence risk after transplantation in the eyes of the investigator.

6. Diagnosis of atypical hemolytic-uremic syndrome or thrombotic microangiopathy at the moment of inclusion

7. Diagnosis of antiphospholipid syndrome at the moment of inclusion

8. Panel-reactive antibodies (PRA) score > 50%

9. Known allergies to any of the components of the perfusate

10. Preexisting vascular disease that represents an extraordinary technical difficulty for the transplantation in the opinion of the investigator

11. Presence of clinically relevant donor-specific anti-HLA antibodies

12. ABO incompatibility

13. History of alcohol or drug abuse in the last two years

14. Use of normothermic regional perfusion during the organ harvesting process

15. Participation of the patient in another study or clinical trial.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 2 patient groups

Experimental group

Experimental group

Description:

Ex vivo normothermic perfusion (EVNP) of the graft with the Ark Kidney System

Treatment:

Device: Ex vivo normothermic perfusion

Historical control group

Active Comparator group

Description:

Nonrandomized historical control group formed by patients transplanted without ex vivo normothermic perfusion (EVNP) in the period Sept 2015-Sept 2020, selected by retrospective matching.

Treatment:

Device: Cold preservation